Future of Healthcare Using Genomics as a Key Tool
Is Focus of HL7’s 24th Annual Plenary Meeting

HL7 to offer CME for Ambassador Program on HL7 and the Meaningful Use Final Rule on Standards for EHR Technology

Ann Arbor, Michigan, USA – August 5, 2010 – Health Level Seven® International (HL7®), the global authority for interoperability and standards in healthcare information technology, today announced the program agenda for the 24th Annual Plenary Meeting – The Future of Healthcare Using Genomics as a Key Tool – held Monday, October 4, 2010 in Cambridge, MA.

“IT’s envisioned that the use of genomic data in healthcare practice will become ubiquitous,” said Bob Dolin, MD, chair of HL7 International. “In fact, it’s hard to imagine a field having broader implications to patient care, whether it is disease prediction, drug safety, disease management, and preventive care.”

Keynotes for the Plenary Meeting include:

- **Implementation of Personalized Medicine** by Raju Kucherlapati, PhD, Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School; Director Emeritus, Harvard Medical School-Partners HealthCare Center for Personalized Genetic Medicine; Principal Investigator, Genome Characterization Center, The Cancer Genome Atlas

- **Personal Genome Project** by George M. Church, PhD, Professor of Genetics at Harvard Medical School and Director of the Center for Computational Genetics, Founder of Personal Genome Project
Panel Presentations on Clinical Genomics include:

- Performing clinical assessment through family health history using HL7 data exchange
- Structuring genetic lab results in the electronic health record via a successfully piloted HL7 data transmission
- Using HL7 clinical genomics standards in genetic research

More information on this year’s plenary program can be found at http://www.hl7.org/events/boston102010/plenary.asp.

The plenary session is held each year as part of HL7’s October Working Group meeting, which will convene from October 3-8, 2010. A special Ambassador Program event on HL7 and the final rule on standards for meaningful use will also be held Monday afternoon immediately following the plenary program. This program will provide an overview of how HL7 will be used to achieve meaningful use and includes high-level tutorials on HL7’s Clinical Document Architecture (CDA), Continuity of Care Document (CCD), and the Version 2 standards, all of which are named in the final rule. Like the majority of HL7’s tutorials offered at the October Working Group Meeting, this Ambassador Program session qualifies for Continuing Medical Education (CME) approved through the American College of Physicians. For more information about this session, please visit http://www.hl7.org/events/boston102010/ambassador.asp.

Online registration is now open. Early bird registration offers a discounted rate through September 10, 2010. To register online, visit http://www.hl7.org/events/boston102010/. Advance registrations will be accepted until September 24, 2010. After September 24, 2010, registrations must be made on-site in Cambridge, MA.

HL7 Working Group meetings are held three times a year to provide its more than 40 work groups a chance to meet together to work on the standards and provide educational sessions for the healthcare IT community.

**About Health Level Seven International (HL7)**

Founded in 1987, Health Level Seven International is the global authority for healthcare information interoperability and standards with affiliates established in more than 30 countries. HL7 is a non-profit, ANSI accredited standards development organization dedicated to providing a comprehensive framework and related standards for the exchange, integration, sharing, and retrieval of electronic health information that supports clinical practice and the management, delivery and evaluation of health services. HL7’s more than 2,300 members represent approximately 500 corporate members, which include more than 90 percent of the information systems vendors serving healthcare. HL7 collaborates with other standards developers and provider, payer, philanthropic and government agencies at the highest levels to ensure the development of comprehensive and reliable standards and successful
interoperability efforts.

HL7’s endeavors are sponsored, in part, by the support of its benefactors: Abbott; Accenture; Booz Allen Hamilton; Centers for Disease Control and Prevention; Duke Translational Medicine Institute (DTMI); Eclipsys Corporation; Epic Systems Corporation; European Medicines Agency; the Food and Drug Administration; GE Healthcare Information Technologies; GlaxoSmithKline; Intel Corporation; InterSystems Corporation; Kaiser Permanente; Lockheed Martin; McKesson Provider Technology; Microsoft Corporation; NHS Connecting for Health; NICTIZ National Healthcare; Novartis Pharmaceuticals Corporation; Oracle Corporation; Partners HealthCare System, Inc.; Pfizer, Inc.; Philips Healthcare; Quest Diagnostics Inc.; Siemens Healthcare; St. Jude Medical; Thomson Reuters; the U.S. Department of Defense, Military Health System; and the U.S. Department of Veterans Affairs.

Numerous HL7 Affiliates have been established around the globe including Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Finland, Germany, Greece, Hong Kong, India, Italy, Japan, Korea, The Netherlands, New Zealand, Norway, Romania, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, and Uruguay.

For more information, please visit: www.HL7.org

# # #